NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
This publication is provided for historical reference only and the information may be out of date.
"Atypical" antipsychotic agents are used to treat the symptoms of schizophrenia and bipolar disorder. The atypical antipsychotics interact with more neurotransmitter receptor types than conventional antipsychotics and vary from one another in receptor interaction selection and affinity. In general, atypical antipsychotics produce antipsychotic responses with fewer acute extrapyramidal side effects than "conventional" antipsychotic drugs. This review addresses the use of atypical antipsychotics to treat schizophrenia, bipolar disorder, behavioral and psychological symptoms of dementia (BPSD) in adults, and pervasive developmental disorders and disruptive behavior disorders in children. The purpose of this review is to help policy makers and clinicians make informed choices about the use of atypical antipsychotics by evaluating their comparative effectiveness and harms.
Contents
The funding source, the Center for Evidence-based Policy, is supported by 14 organizations, including 13 state Medicaid programs. These organizations selected the topic and had input into the Key Questions for this review. The content and conclusions of the review are entirely determined by the Evidence-based Practice Center researchers. The authors of this report have no financial interest in any company that makes or distributes the products reviewed in this report.
Suggested citation:
McDonagh MS, Peterson K, Carson S, Chan B, Thakurta S. Drug class review on atypical antipsychotic drugs. Update #2 final report. http://www.ohsu.edu/drugeffectiveness/reports/final.cfm
The purpose of this report is to make available information regarding the comparative effectiveness and safety profiles of different drugs within pharmaceutical classes. Reports are not usage guidelines, nor should they be read as an endorsement of, or recommendation for, any particular drug, use or approach. Oregon Health & Science University does not recommend or endorse any guideline or recommendation developed by users of these reports.
- Review Behavioral and Psychological Symptoms in Dementia (BPSD) and the Use of Antipsychotics.[Pharmaceuticals (Basel). 2021]Review Behavioral and Psychological Symptoms in Dementia (BPSD) and the Use of Antipsychotics.Calsolaro V, Femminella GD, Rogani S, Esposito S, Franchi R, Okoye C, Rengo G, Monzani F. Pharmaceuticals (Basel). 2021 Mar 9; 14(3). Epub 2021 Mar 9.
- Review Use of antipsychotics in elderly patients with dementia: do atypical and conventional agents have a similar safety profile?[Pharmacol Res. 2009]Review Use of antipsychotics in elderly patients with dementia: do atypical and conventional agents have a similar safety profile?Trifirò G, Spina E, Gambassi G. Pharmacol Res. 2009 Jan; 59(1):1-12. Epub 2008 Oct 8.
- Review Antipsychotic safety and efficacy concerns.[J Clin Psychiatry. 2007]Review Antipsychotic safety and efficacy concerns.Meyer JM. J Clin Psychiatry. 2007; 68 Suppl 14:20-6.
- Review Atypical antipsychotics in elderly patients with dementia or schizophrenia: review of recent literature.[Harv Rev Psychiatry. 2005]Review Atypical antipsychotics in elderly patients with dementia or schizophrenia: review of recent literature.Jeste DV, Dolder CR, Nayak GV, Salzman C. Harv Rev Psychiatry. 2005 Nov-Dec; 13(6):340-51.
- Review Using antipsychotic agents in older patients.[J Clin Psychiatry. 2004]Review Using antipsychotic agents in older patients.Alexopoulos GS, Streim J, Carpenter D, Docherty JP, Expert Consensus Panel for Using Antipsychotic Drugs in Older Patients. J Clin Psychiatry. 2004; 65 Suppl 2:5-99; discussion 100-102; quiz 103-4.
- Drug Class Review: Atypical Antipsychotic DrugsDrug Class Review: Atypical Antipsychotic Drugs
- Serpula lacrymans var. lacrymans S7.9Serpula lacrymans var. lacrymans S7.9S7.9 monokaryon genome, originating from the S7 dikaryonBioProject
- Drug Class Review on Newer AntiemeticsDrug Class Review on Newer Antiemetics
- Drug Class Review: Cyclo-oxygenase (COX)-2 Inhibitors and Non-steroidal Anti-inf...Drug Class Review: Cyclo-oxygenase (COX)-2 Inhibitors and Non-steroidal Anti-inflammatory Drugs (NSAIDs)
Your browsing activity is empty.
Activity recording is turned off.
See more...